155 related articles for article (PubMed ID: 38602224)
21. Trend of nontuberculous mycobacteria species and minimal inhibitory concentration in a referral laboratory in Korea from 2013 to 2019.
Kim YJ; Kim S; Ham H; Yu S; Choo HJ; Kim HJ; Heo R; Choi G; Kim SH; Lee HJ
J Infect Public Health; 2024 Feb; 17(2):212-216. PubMed ID: 38113818
[TBL] [Abstract][Full Text] [Related]
22.
Brown-Elliott BA; Rubio A; Wallace RJ
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126964
[TBL] [Abstract][Full Text] [Related]
23. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
24. Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.
Boorgula GD; Gumbo T; Singh S; McShane PJ; Philley JV; Srivastava S
Tuberculosis (Edinb); 2024 Jul; 147():102519. PubMed ID: 38754247
[TBL] [Abstract][Full Text] [Related]
25. CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates.
Lee MR; Cheng A; Lee YC; Yang CY; Lai CC; Huang YT; Ho CC; Wang HC; Yu CJ; Hsueh PR
J Antimicrob Chemother; 2012 Jan; 67(1):222-5. PubMed ID: 21980068
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases.
Huh HJ; Kim SY; Jhun BW; Shin SJ; Koh WJ
Infect Genet Evol; 2019 Aug; 72():169-182. PubMed ID: 30315892
[TBL] [Abstract][Full Text] [Related]
27. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report.
Kim SY; Shin SJ; Jeong BH; Koh WJ
BMC Infect Dis; 2016 May; 16():207. PubMed ID: 27188784
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial Susceptibility Distributions of Clinical Isolates of Nontuberculous Mycobacteria in Israel.
Hershko Y; Adler A
Microb Drug Resist; 2023 Jul; 29(7):302-308. PubMed ID: 37219996
[TBL] [Abstract][Full Text] [Related]
29.
Kim DH; Zo S; Kim SY; Jhun BW
Ann Lab Med; 2024 Jan; 44(1):92-96. PubMed ID: 37665290
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology of Nontuberculous Mycobacteria in Tuberculosis suspects, Southwest of China, 2017-2022.
Wang DM; Liu H; Zheng YL; Xu YH; Liao Y
Front Cell Infect Microbiol; 2023; 13():1282902. PubMed ID: 38029240
[TBL] [Abstract][Full Text] [Related]
31. Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex.
Rubio M; March F; Garrigó M; Moreno C; Español M; Coll P
PLoS One; 2015; 10(10):e0140166. PubMed ID: 26448181
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of carvacrol against resistant rapidly growing mycobacteria in the planktonic and biofilm growth mode.
Marini E; Di Giulio M; Ginestra G; Magi G; Di Lodovico S; Marino A; Facinelli B; Cellini L; Nostro A
PLoS One; 2019; 14(7):e0219038. PubMed ID: 31260476
[TBL] [Abstract][Full Text] [Related]
33. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense.
Park J; Cho J; Lee CH; Han SK; Yim JJ
Clin Infect Dis; 2017 Feb; 64(3):301-308. PubMed ID: 28011609
[TBL] [Abstract][Full Text] [Related]
34. The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria.
Pennings LJ; Ruth MM; Wertheim HFL; van Ingen J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468478
[TBL] [Abstract][Full Text] [Related]
35. Rifabutin Is Active against Mycobacterium abscessus in Mice.
Dick T; Shin SJ; Koh WJ; Dartois V; Gengenbacher M
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767722
[TBL] [Abstract][Full Text] [Related]
36. The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex.
Takei S; Ihara H; Togo S; Nakamura A; Fujimoto Y; Watanabe J; Kurokawa K; Shibayama K; Sumiyoshi I; Ochi Y; Iwai M; Okabe T; Chonan M; Misawa S; Ohsaka A; Takahashi K
BMC Microbiol; 2020 Oct; 20(1):316. PubMed ID: 33076820
[TBL] [Abstract][Full Text] [Related]
37. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
38. Non-Tuberculous Mycobacteria multispecies biofilms in cystic fibrosis: development of an in vitro Mycobacterium abscessus and Pseudomonas aeruginosa dual species biofilm model.
Rodríguez-Sevilla G; García-Coca M; Romera-García D; Aguilera-Correa JJ; Mahíllo-Fernández I; Esteban J; Pérez-Jorge C
Int J Med Microbiol; 2018 Apr; 308(3):413-423. PubMed ID: 29555180
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense.
Zhang Z; Lu J; Liu M; Wang Y; Zhao Y; Pang Y
Int J Antimicrob Agents; 2017 Mar; 49(3):383-386. PubMed ID: 28188830
[TBL] [Abstract][Full Text] [Related]
40.
Kim DH; Kim SY; Koh WJ; Jhun BW
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0230620. PubMed ID: 33903101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
